Factors Associated with Peripheral Blood Stem Cell Yield in Volunteer Donors Mobilized with Granulocyte Colony-Stimulating Factors: The Impact of Donor Characteristics and Procedural Settings  by Wang, Tso-Fu et al.
Factors Associated with Peripheral Blood Stem Cell
Yield in Volunteer Donors Mobilized with Granulocyte
Colony-Stimulating Factors: The Impact of Donor
Characteristics and Procedural Settings
Tso-Fu Wang,1 Shu-Hui Wen,4 Rong-Long Chen,2 Chi-Jui Lu,6 Ya-Jun Zheng,3 Shang-
Hsien Yang,2 Sung-Chao Chu,1 Ruey-Ho Kao,1,5 Shu-Huey Chen2,5,6
Peripheral blood stem cells (PBSCs) are increasingly used as the source of hematopoietic stem cells, but
there are large variations in harvest outcome between individuals mobilized by granulocyte colony-stimulat-
ing factor (G-CSF). We examined the effects of donor characteristics and procedure factors on the day 1
CD341 cell yield in 373 unrelated healthy donors. G-CSF was administered subcutaneously at a planned
dose of 8.3 to 11mg/kg daily for 5 days, followed by harvest started on day 5 of G-CSF treatment. Of the
373 donors, 159 (42.6%) had the radial artery as the inlet access for harvest. Poor day 1 cell yield was defined
as\10 106 CD341 cells/L of processed blood for the first apheresis; 62 donors (16.6%) did not attain this
threshold. The male donors had significantly higher yields at harvest compared with the female donors. The
female donors had higher CD341 cell yields if the circulation access was through an artery than if is was
through a vein. In a multiple regression analysis, donor age, sex, body mass index (BMI), preharvest white
blood cell and circulating immature cell counts, access type, and flow rate correlated with day 1 yield. Female
sex, older age, venous access, and a higher flow rate were significantly associated with greater risk for a day 1
poor yield of CD341 cells (odds ratio5 3.0074, 1.045, 4.3362, and 1.1131, respectively). A higher BMI may
decrease the risk (odds ratio 5 0.8472). In donors at higher risk for poor CD341 cell yield, strategies for
increasing CD341 cells must be considered.
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ApheresisINTRODUCTION
Allogeneic hematopoietic stem cell transplantation
(HSCT) has been used to treat a wide variety of malig-
nant and nonmalignant hematologic diseases. Periph-
eral blood stem cells (PBSCs) are increasingly used as
the source of stem cells in HSCT because of improved
neutrophil and platelet engraftment, avoidance of gen-
eral anesthesia for collection, and potentially better
graft-versus-leukemia effect [1,2].
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doi:10.1016/j.bbmt.2008.09.002A high stem cell dose may be associated with im-
proved hematopoietic recovery and survival in patients
undergoingHSCT. Large variations exist among indi-
viduals mobilized by granulocyte colony-stimulating
factor (G-CSF), however. Poor mobilization is cur-
rently defined as collection of \ 2  106 CD341
cells/kg of recipient body weight (BW), which may
be associated with prolonged or incomplete engraft-
ment [3,4]. In some patients, mobilizationmay be inef-
fective to allow collection of this threshold dose. Even
in healthy individuals used for allogeneic transplants,
these poor mobilizers may represent up to 20% of do-
nors [5]. Although some previous reports have focused
on the donor features associated with stem cell yields,
currently there are no well-accepted criteria for identi-
fying a poor mobilizer. This might be related to vari-
ability in study design and conclusions.
As the number of stem cell volunteer donors has
increased worldwide, the number of patients with sev-
eral well-matched HLA donors also has increased. A
recent study found that 56% of patients will have1305
1306 Biol Blood Marrow Transplant 14:1305-1311, 2008T.-F. Wang et al.$ 10 HLA-matched adult donors in the current
National Marrow Donor Program (NMDP) files [6].
Identifying factors associated with a better quality
and greater quantity of stem cells may provide an op-
portunity to enhance patient recovery while maintain-
ing a safe process for stem cell donation for the donors.
In an attempt to gain insight into the donor factors that
may affect the quantity of stem cell collection from
volunteer donors, we retrospectively analyzed the rela-
tionship between the harvest yields of CD341 cells on
first apheresis and the characteristics of volunteer do-
nors from the Tzu-Chi stem cell donor registry. We
also studied the impact of the apheresis procedures,
which has not been evaluated in depth to date.
METHODS
Donors and Mobilization
Between January 2003 and March 2008, a total of
375 healthy unrelated volunteers underwent PBSC
harvesting in our institution and were eligible for this
retrospective analysis. All donors agreed to PBSC do-
nation after being informed about the procedures for
both bone marrow harvest and PBSC collection. Be-
fore donation, a complete medical history, physical ex-
amination, and laboratory analysis, including a blood
test, electrocardiogram, and chest X-ray, were per-
formed. Informed consent was obtained from each
participant. Two donors (0.5%) were excluded from
the analysis because of failure to obtain consent or in-
complete data. This retrospective study was approved
by the local institutional review board.
For stem cell mobilization, G-CSF (filgrastim;
Kirin Brewery Co, Tokyo, Japan) was administered
s.c. at a dose of 10 mg/kg of donor BW once a day
for 5 consecutive days in all donors. Each donor re-
ceived the G-CSF at local clinics at approximately
the same time every day. To avoid calculation errors,
the actual dose was determined at the time of the donor
health examination and simplified to fit the combina-
tion of available dosage forms. The G-CSF dosages
ranged from 8.3 to 11 mg/kg, as shown in Table 1.
PBSC Collection
Leukapheresis was performed with a continuous-
flow cell separator (Cobe Spectra; Cobe Laboratories,
Denver, CO) at a planned flow rate of 40 to 60 mL/
minute. The actual flow rate was calculated by dividing
the total processed blood volume (mL) by the process-
ing time (min). The circulation system was accessed
from bilateral antecubital veins by means of a 16- to
18-gauge catheter for both the inlet and the return
line or by a radial artery 20-gauge catheter as the inlet
line and a 16- or 18-gauge catheter in the antecubital
vein as the return line. The use of arterial or venouscirculation as the inlet was at the discretion of each
apheresis physician after evaluating the donor’s vascu-
lar access and his or her willingness. In brief, venous
catheterization was the first choice. If achieving 2 large
venous accesses was deemed difficult (based on the
physician’s experience or by more than 3 trials), then
an arterial access was considered. In donors with
a low flow rate (\ 30 mL/min), the physician may de-
cide to change the access site to an artery to obtain an
adequate flow rate. For donors in whom peripheral ve-
nous and arterial access was difficult, central venous
catheters were placed in the femoral vein. The apher-
esis procedure was started approximately 3 hours (at
noon) after administration of the fifth G-CSF dose.
If a second apheresis was necessary, then the procedure
was performed on the morning of the next day.
CD341 Cell Counts
Peripheral blood cell counts before apheresis and
PBSC component counts were obtained using an auto-
mated cell counter (model SE-9000; Sysmex Corp,
Kobe, Japan). White blood cells (WBCs), circulating
immature cells (CICs), platelets, and CD341 cells
were counted for analysis. CICs were was defined as
circulating myeloblasts, promyelocytes, myelocytes,
metamyelocytes, and erythroblasts detected by mor-
phology in a peripheral blood smear; their counts
were calculated by multiplying a percentage of the
CICs by each donor’s WBC count.
The number of CD341 cells was enumerated from
the resultant leukapheresis bag by flow cytometry anal-
ysis. In brief, 50 mL of leukapheresis product was incu-
bated with 20 mL of control reagent or CD34 reagent
in individual bead-containing TruCOUNT tubes
(ProCOUNT kit; BD, San Jose, CA). The Pro-
COUNT CD34 reagent contained a nucleic acid
dye, phycoerythrin (PE)-labeled murine monoclonal
anti-CD34 antibody, and peridinin chlorophyll pro-
tein (PerCP)-labeled anti-CD45 antibody, whereas
the control reagent contained a nucleic acid dye,
PE-labeled IgG1, and PerCP-labeled anti-CD45 anti-
body. After red cell lysis with lysing solution, the
CD341 cell count was performed using a flow cytom-
eter (FACSCalibur; BD) and ProCOUNT software
packages (BD). At least 60,000 CD45 events and
1000 BD TruCOUNT tube beads were collected in
each sample. Samples were analyzed according to the
gating strategy as described previously [7]. Nucleic
acid dye versus side-scattering cytogram (SSC) and
CD45 PerCP versus SSC dot plots were used to
exclude cellular debris and any event with bright
Table 1. G-CSF Dose According to Donor BW
Donor BW, kg 45-54 55-69 70-85 86-95 96-100 101-115 >116
G-CSF dose, mg 450 600 750 900 975 1050 1200
Biol Blood Marrow Transplant 14:1305-1311, 2008 1307Factors Associated with PBSC Yield in Volunteer DonorsCD45 or high SSC, which are not characteristic of
progenitor cells. The CD341 cell population was de-
fined in the nucleic acid dye versus the CD34 PE of
cells gated from previous additive regions. The abso-
lute number of CD341 cells in the sample was deter-
mined by dividing the number of CD341 cellular
events by the number of fluorescent bead events and
then multiplying this by the bead concentration.
Stem cell yield was defined as the number of CD341
cells/L of processed blood. To obtain an accurate eval-
uation, only results of the first apheresis were consid-
ered in the analysis of factors affecting harvest yields.
A day 1 CD341 cell count of\10 106/L was consid-
ered a poor yield in our outcome analysis.
Statistics
Descriptive statistics, including mean and range,
were calculated, and age, body mass index (BMI),
and apheresis products for male and female donors
were compared using the 2-sample t-test and the c2
test. BMI was defined as the individual’s body weight
in kilograms divided by height squared in meters (kg/
m2). The means of procedural variables, including
flow rate, processed volume, and day 1 CD341 cell
yield for arterial and venous accesses, were compared
using 2-sample t-tests based on all data and by strati-
fied sex group separately. Multiple regression was
used to analyze the correlations among potential fac-
tors, including donor characteristics, procedural vari-
ables, and day 1 CD34 cell1 yields. The risk for poor
day 1 CD341 cell yields was evaluated using a logistic
regression model in which odds ratio (OR) indicated
the strength of the risk. A test was considered statisti-
Table 2. Descriptive Statistics of Donor Characteristics and
Procedural Variables in Volunteer Donors (n5373)
Characteristic Mean
Median
(Range)
Sex*
Male 230 (61.7%)
Female 143 (38.3%)
Age, years 31.2 30 (20-54)
BMI, kg/m2 23.2 22.7 (16.1-38.3)
Inlet lines*
Artery 159 (42.6%)
Vein 214 (57.4%)
G-CSF dose, mg/kg 9.7 9.6 (7.0-11.0)
Day 1 actual flow rate, mL/min 44.4 44.4 (20.7-67.5)
Total day 1 processed blood volume, L 16.5 18.0 (7.5-18.6)
Day1 processed blood volume per
donor BW, mL/kg
262.7 264.8 (86.6-428.7)
Preapheresis WBC count, 103/mL 44.2 42.7 (16.6-80.7)
Preapheresis platelet count, 103/mL 200.0 197 (77-371)
Preapheresis CIC count, 103/mL 2.4 2.1 (0-9.2)
Day 1 total CD34+ cell count, 106 416.1 378.3 (19.0-1425.1)
Day 1 CD34+ cells per donor BW, 106/kg 6.4 5.9 (0.3-22.6)
Day 1 CD34+ cells per recipient BW, 106/kg 7.3 6.2 (0.3-34.6)
Day 1 CD34+ cell yield, 106/L of processed
blood
25.4 23.0 (1.1-101.0)
*Data presented as number (%).cally significant when the P value was\ .05. All anal-
yses were implemented using the SPSS 13.0
statistical package (SPSS Inc, Chicago, IL).
RESULTS
Donor Characteristics
Table 2 summarizes descriptive statistics of the do-
nors’ characteristics, procedural variations, and yields
at stem cell harvest. The mean donor age was 31.2
years, with a predominance of males (61.7%). The
mean G-CSF dose was 9.7 mg/kg. It was the first stem
cell donation and PBSC mobilization for all donors.
A total of 214 donors (57.4%) were accessed with
a vein as the apheresis inlet; 3 donors required a central
venous catheter. Themean day 1 processed volumewas
262.7mL/kg of donorweight or, in otherwords, 16.5L
total. Themean day 1CD341 cell count, cell yield, and
recipient cell dosewere 416.1 106 cells, 25.4 106/L,
and 7.3  106/kg of recipient BW, respectively. Ac-
cording to our definition of day 1 poor yield, 62 donors
(16.6%) had a yield\10 106 CD341 cells/L of pro-
cessed blood after the first apheresis.
Recipient Threshold
A total of 226 donors (60.6%) achieved the goal of
a CD341 cell dose of 5 106/kg of recipient BW after
the first apheresis procedure. Of the 147 donors with
a day 1 harvest\5  106/kg, 123 underwent a second
apheresis on the next day. After a maximum of 2 apher-
eses, 247 (66.2%) donations achieved the required
dose. Although all 37 donors who attained a day 1
CD341 cell count of\2 106/kg underwent a second
apheresis, 17 (4.6%) of donors still had a recipient cell
dose below the required threshold. The percentage of
donors who met the common optimal CD341 cell
dose criterion of $ 4  106/kg of recipient BW was
70.8% after 1 apheresis and 79.1% after 2 aphereses
(Table 3).
Factors Affecting Day 1 PBSC Yield
Considering the influence of sex, the male donors
had significantly higher mean day 1 total CD341 cell
count (P\ .0001), cell yield (P\ .0001), and recipient
cell dose (P\ .0001) compared with the female donors
(Table 4). The male donors had higher BMI, total pro-
cessed volume, and flow rate but lower preapheresis
Table 3. Donor Percentage that Met Different Harvest Out-
come Criteria of CD34+ Cell Count According to Recipient
BW
$ 5  106/kg $ 4  106/kg # 2  106/kg
First apheresis 60.6% 70.8% 9.9%
Final product 66.2% 79.1% 4.6%
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and arterial access percentage. Age, G-CSF dose, and
preapheresis WBC and CIC counts did not differ be-
tween the sexes.
Regarding the effect of access type, use of a radial ar-
tery as the inlet access was associated with a higher flow
rate and lower total processed volume. The stem cell
harvest outcomesdidnotdiffer significantly basedonar-
terial or venous access except in a subgroupof female do-
nors (Table 5). The mean day 1 CD341 cell count and
cell yield were obviously higher in females with arterial
access compared with those with venous access, even
though the recipient cell dose was not significantly dif-
ferent between the 2 subgroups (P5 .0852).
Table 4. Mean Comparisons of Age, BMI, G-CSF Dose, and
Apheresis Products for Male and Female Donors
Male Female P Value
Age, years 30.9 31.7 .3053
BMI, kg/m2 24.3 21.5 < .0001
G-CSF dose, mg/kg 9.7 9.6 .2863
Preapheresis WBC count, 103/mL 43.5 45.5 .1087
Preapheresis platelet count, 103/mL 189.1 217.1 < .0001
Preapheresis CIC count, 103/mL 2.54 2.23 .1096
Artery access* 33.9% 56.6% < .0001
Day 1 actual flow rate, mL/min 45.0 43.1 .0017
Total day 1 processed volume, L 16.9 15.9 < .0001
Day 1 processed volume per donor BW, mL/kg 242.0 297.4 < .0001
Day 1 total CD34+ cell count, 106 483.2 310.5 < .0001
Day 1 CD34+ cells per donor BW, 106/kg 6.9 5.7 .0023
Day 1 CD34+ cells per recipient BW, 106/kg 8.2 6.0 < .0001
Day 1 CD34+ cell yield, 106/L of processed
blood
28.9 19.8 < .0001
Note. Unless noted otherwise, data are presented as mean; P value was
derived from the 2-sample t-test, 2-tailed, except for artery access.
*Data presented as percentage; P value was calculated by the c2 test.
Table 5. Mean Comparisons Between Donors Accessed with
Artery or Vein as the Apheresis Inlet
Artery Vein P Value
Day 1 actual flow rate, mL/min 47.0 42.5 < .0001
Male 48.9 43.4 < .0001
Female 45.1 40.3 < .0001
Total day 1 processed volume, L 16.1 16.8 .0031
Male 16.2 17.1 .0004
Female 16.0 15.8 .7849
Day 1 processed volume per donor BW, mL/kg 263.2 262.3 .8920
Male 233.8 244.9 .0950
Female 291.5 305.2 .2036
Total day 1 CD34+ cell count, 106 408.0 422.1 .5987
Male 467.3 489.0 .5600
Female 350.8 257.8 .0041
Day 1 CD34+ cells per donor BW, 106/kg 6.42 6.35 .8594
Male 6.62 6.94 .5404
Female 6.23 4.90 .0168
Day 1 CD34+ cells per recipient BW, 106/kg 7.44 7.23 .7017
Male 8.30 8.07 .7566
Female 6.61 5.16 .0852
Day 1 CD34+ cell yield, 106/L of processed
blood
25.4 25.4 .9970
Male 29.1 28.8 .9128
Female 21.9 17.0 .0182
Note. Data are presented as mean, and P value was derived from a 2-
sample t-test, 2-tailed.In multiple regression analysis, factors signifi-
cantly correlated with day 1 CD341 cell yields were
donor age, BMI, sex, access type, flow rate, and prea-
pheresis WBC and CIC counts (Table 6). Age and
flow rate were negatively correlated with cell yield,
whereas BMI and preapheresis WBC and CIC counts
were positively correlated with cell yield. G-CSF dose
and first day total processed blood volume did not af-
fect the number of CD341 cells/L of processed blood.
Regarding the OR of each factor for poor day 1
CD341 cell yield (\ 10  106/L of processed blood
volume), female sex (OR 5 3.0074), older age (OR 5
1.045), venous access (OR 5 4.3362), and higher
flow rate (OR 5 1.1131) were significantly associated
with increased risk based on logistic regression analy-
sis. A higher BMI was associated with a lower risk (OR
5 0.8472). There was a trend of decreased risk for day
1 poor yield in donors with higher preapheresis labora-
tory data, but the P value was not significant. The risks
associated with each factor are summarized in Table 7.
Procedure Tolerability
Most donors toleratedG-CSF administration well.
Only 1 donor required a dosage reduction due to side
effects of G-CSF. Her G-CSF dose was reduced to
Table 6. Multiple Regression Model of Donor Characteristics
and Procedural Variables on Day 1 CD34+ Cell Yield
Coefficient Standard Error P Value
Sex* 28.7797 1.6242 < .0001
Age, years 20.3001 0.0909 .0010
BMI, kg/m2 0.9381 0.1979 < .0001
G-CSF dose, mg/kg 1.6088 0.9440 .0892
Access† 24.3452 1.5518 .0054
Flow rate, mL/min 20.4602 0.1292 .0005
Total processed volume, L 20.1760 0.3139 .5754
Preapheresis WBC count, 103/mL 0.1695 0.0695 .0152
Preapheresis platelet count, 103/mL 0.0277 0.0155 .0750
Preapheresis CIC count, 103/mL 2.0818 0.4414 < .0001
*Male is coded as 1; female, as 2.
†Artery is coded as 1; vein, as 2.
Table 7. OR Estimates of Influential Factors for a Poor Yield
of Day 1 CD34+ Cells (< 2  106/L of Processed Blood)
OR
95% Confidence
Interval P Value
Sex* 3.0074 1.3825-6.5422 .0055
Age, years 1.0450 1.0015-1.0904 .0425
BMI, kg/m2 0.8472 0.7539-0.9522 .0054
G-CSF dose, mg/kg 0.6938 0.4515-1.0660 .0953
Access† 4.3362 1.9076-9.8565 .0005
Flow rate, mL/min 1.1131 1.0389-1.1927 .0023
Total processed volume, L 1.0002 0.8539-1.1716 .9976
Preapheresis WBC count, 103/mL 0.9658 0.9328-1.0000 .0502
Preapheresis platelet count, 103/mL 0.9929 0.9858-1.0001 .0533
Preapheresis CIC count, 103/mL 0.8343 0.6555-1.0618 .1409
*Male is coded as 1; female, as 2.
†Artery is coded as 1; vein, as 2.
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nausea, and severe headache and bone pain; her final
average daily G-CSF dose was 7.0 mg/kg. Two other
donors received a lower G-CSF dosage than initially
planned. One donor had a dosage of 7.8 mg/kg, based
on a rapid increase in BW (from 54 kg to 57.5 kg) after
the health examination; the other donor had a dosage
of 7.1 mg/kg due to a clerical error in the calculation
of his BW. No donor required a reduced G-CSF dos-
age because of a high leukocyte count (. 75,000/mL)
on the third day of mobilization.
All donors tolerated the apheresis procedure.
Symptoms related to hypocalcemia, such as numbness
and muscle cramps, were the most common adverse
events; these resolved with calcium gluconate infusion
and did not necessitate stopping the procedure. Two
donors with radial artery access experienced a local he-
matoma after catheter removal; both had completely
recovered at follow-up. No major morbidity or mor-
tality related to catheterization was noted. One donor
experienced nasal bleeding during the harvest, al-
though his platelet count was 171,000/mL before
apheresis and 71,000/mL after apheresis. The bleeding
was easily stopped by local compression. No other
bleeding diathesis was noted.
DISCUSSION
Althoughmobilized PBSCs are widely used in allo-
geneic HSCT, relatively little information is available
about the factors predicting the outcome of stem cell
collection from healthy volunteers. Previous studies
have used different settings for apheresis equipment
and different protocols, varied the type and dosages
of G-CSF, used various parameters for outcome anal-
ysis, and reported different final results (Supplemental
Table) [8-16].
Final infused cell dose is frequently used as the out-
come indicator when analyzing the impact of donor
characteristics on PBSC harvest. Today, most harvest
centers perform at least 2 aphereses if the first product
does not achieve the target cell dose. The repeated
aphereses may mask the impact of donor factors on
stem cell harvest by different numbers of aphereses
among donors and also may lead to bias due to differ-
ences in criteria for a second apheresis among institu-
tions. Consequently, using the final number of
CD341 cells collected as the dependent variable may
be inappropriate [9]. In addition, most previous studies
have adjusted the CD341 cell dose based on donor or
recipient BW or on the volume of blood processed to
standardize the yields among donors. A very high or
low recipient weight will misclassify the donor into
wrong outcome group in analysis, however. Further-
more, donor BW is not a useful factor for adjustment
because it is not modifiable, and it should be investi-gated because many studies have demonstrated its
effect on stem cell yield.
Based on the foregoing rationale, we used the
number of CD341 cells/L of processed blood volume
collected during the first apheresis to identify donor-
specific factors and procedures associated with the out-
come of harvest after 1 apheresis. Collection of\10
106 CD341 cells/L of processed blood volume was de-
fined as a poor yield based on a maximum of 2 apher-
eses of a total of 24 L of processed blood volume,
yielding 4  106 CD341 cells/kg for a recipient with
BW of 60 kg. We believe that this cutoff defines
a more precise group of donors with low harvest out-
come compared with the traditional criterion for
a poor mobilizer (CD341 cells\2  106/kg of recip-
ient BW), which is confounded by the recipient BW.
This threshold for a poor day 1 yield corresponds to
high sensitivity (94.6%) and adequate specificity
(91.7%) for day 1 CD341 cells\2  106/kg of recip-
ient BW in our cohort (Figure 1).
In our findings, significant donor factors, such as
age, BMI, and preapheresis laboratory results, had lit-
tle impact on risk, consistent with most previous stud-
ies showing weak correlations of these factors with
stem cell yields. This also might be the reason why
the results for these donor factors were not always sig-
nificant in previous studies (Supplemental Table). An-
derlini et al. [8] reported that donor age. 55 years was
associated with a 3.8-fold greater risk of poor mobili-
zation. The much lower OR for age in our study
(1.045) could be related to the relatively homogeneous
nature and younger age of our donor population (mean
age, 31 years; range, 20 to 54 years vs median age, 38
years; range, 4 to 77 years of Anderlini et al.). In con-
trast to the donor factors that had little impact, we
noted that female sex had a lower mean harvest out-
come and a higher risk for poor yield in our cohort.
Sex was considered to have no effect on stem cell yield
in many previous studies [9,13], although a positive
correlation was suggested by others [11,17]. Two re-
cent large studies found higher total final CD341
cell count and cell yield in male donors [15,18]. A dif-
ferent interaction between G-CSF and sex also has
been suggested, based on superior mobilization in
a male donor by glycosylated G-CSF [18]. This hy-
pothesis is consistent with a recent finding by Vasu
et al. [16] demonstrating significantly lower numbers
of post-G-CSF circulating CD341 cells in female do-
nors. In poor mobilizers treated withG-CSF for autol-
ogous transplantation, the peripheral CD341 cell
concentration may reach a peak 3 to 4 days later com-
pared with ordinary donors [19], or higher doses of
G-CSFmay be required [20]. The true underlying rea-
sons for the relatively poor mobilization by G-CSF in
female donors remain to be elucidated.
The outcome of stem cell harvest depends on 2
steps: mobilization and harvest. Vasu et al. [16]
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post–G-CSF circulating CD341 cell counts, which
truly represent the outcome of mobilization. But
most previous studies have examined final stem cell
harvest yield with donor factors only; relatively few
have described procedural factors affecting the out-
come of PBSC collection. Some recent studies have fo-
cused on the effect of large-volume leukapheresis
(LVL). Although LVL may indeed increase final
stem cell yield, other possible procedural factors,
such as flow rate and circulation access, also may in-
crease yield.
Suzuya et al. [14] investigated donor and proce-
dural factors associated with PBSC yield but in a small
population (n5 59). Their procedural setting was sim-
ilar to ours in terms of flow rate (15 to 70 mL/min),
processed volume (150 to 300 mL/kg), and percentage
of access type (51.5% arterial access). These investiga-
tors also concluded that flow rate was negatively corre-
lated with the outcome of stem cell harvest. Mean
numbers of mononuclear cells, CD341 cells, and gran-
ulocyte-macrophage colony-forming units (GM-
CFU) were all higher in the arterial access group
(0.84 vs 0.43  108/kg/L, 0.57 vs 0.40  106/kg/L,
and 1.55 vs 0.70  105/kg/L, respectively); however,
the differences between the arterial and venous groups
did not reach statistical significance except for that in
GM-CFU (P 5 .016). Although in our study, the
mean harvest stem cell counts also did not differ signif-
icantly between the 2 access groups when the data are
Figure 1. Receiver operating characteristic (ROC) curve for day 1
CD341 cell yields from healthy donors. The ROC curve for day 1
CD341 cell yields with poor mobilization as measure by traditional cri-
teria (\2 106 CD341 cells/kg of recipient BW) is shown. In predicting
day 1 poor mobilization, a cutoff value of\ 10  106 for day 1 CD341
cell yield gives a sensitivity of 94.6% and a specificity of 91.7%.viewed as a whole, the female donors with venous ac-
cess did exhibit lower CD341 cell yields. We also
found an association between venous access and in-
creased risk for poor stem cell yield on logistic regres-
sion analysis. This finding is difficult to explain;
however, a previous report suggested a decrease in cir-
culating hematopoietic progenitor cells after infusion
due to trapping in the pulmonary circulation [21].
Trapping of the relatively large and stiff progenitor
cells in the pulmonary microcirculation is thought be
the main underlying mechanism of leukostasis in pa-
tients with acute leukemia. The trapping that occurs
in pulmonary capillaries also may develop systemi-
cally. Consequently, arterial apheresis will have
a smaller trapping effect than venous apheresis, be-
cause of the smaller capillary area in pulmonary circu-
lation compared with systemic circulation. The more
significant affect of access type in female donors might
be due to the impact of circulation access, which would
be more obvious in a situation of low circulating stem
cells. Further investigation of this phenomenon is
needed to ensure the optimum strategy for the apher-
esis procedure.
The actual flow rate in our study was relatively
slow compared with previous studies; nonetheless,
most donors (98.4%) had a flow rate exceeding the
30 mL/min suggested by the manufacturer. In addi-
tion, our flow rate was very similar that used in a previ-
ous Japanese study [14], which also had a high
percentage of arterial access-type donors. Our donors
typically complained about nonspecific discomfort
during apheresis with a higher flow rate, so our actual
flow rate was not always equal to our planned flow rate.
This may be due to the relatively larger body size and
total blood volume in our sudy cohort compared with
the Japanese cohort, and also likely to the greater oxy-
genation shunting in arterial access. The flow rate was
not clearly defined or even described in previous stud-
ies of factors affecting stem cell harvest outcome. An
optimal flow rate may need to be confirmed in a pro-
spective setting, because its OR was not very high in
our retrospective analysis.
In conclusion, we found that female sex, older age,
higher flow rate, and venous access were significantly
associated with increased risk for poor day 1 CD341
cell yield (\10  106/L of processed blood). A higher
BMI may decrease the risk. In a donor with multiple
high-risk characteristics for poor CD341 cell yield
(eg, an older female with a lower BMI), strategies
for increasing CD341 cell yield must be considered
besides repeated apheresis. The possibility of arterial
access should be evaluated during the preharvest
health examination, and a relatively lower flow rate
of apheresis may be planned, in addition to repeated
apheresis. Other strategies to increase circulating
stem cells, such as a higher or multiple daily dose of
G-CSF or a combination of G-CSF and granulocyte
Biol Blood Marrow Transplant 14:1305-1311, 2008 1311Factors Associated with PBSC Yield in Volunteer Donorsmacrophage colony-stimulating factor, may be prom-
ising approaches [17,22,23]. Bone marrow stem cells
may be used as an alternative source in female donors,
because our data showed no correlation between sex
and nucleated cell density in bone marrow harvest
(unpublished data). The underlying mechanisms by
which these factors affect stem cell harvest merit fur-
ther investigation.
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